Ushbu ish iqtibos qilgan ishlar
171 ta ish
Ish: Exploring cellular immunotherapy platforms in multiple myeloma
Nano based drug delivery systems: recent developments and future prospects
Jayanta Kumar Patra, Gitishree Das, Leonardo Fernandes Fraceto +9
Sharh maqolaOchiq kirish201811 iqtibosABIIdecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C. Munshi, Larry D. Anderson, Nina Shah +25
Maqola20217 iqtibosABINeoantigens: promising targets for cancer therapy
Na Xie, Guobo Shen, Wei Gao +3
Sharh maqolaOchiq kirish20236 iqtibosABIAnti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje, Jesús G. Berdeja, Yi Lin +20
MaqolaOchiq kirish20195 iqtibosABIBispecific T‐cell engagers for cancer immunotherapy
Amelia M. Huehls, Tiffany A. Coupet, Charles L. Sentman
Sharh maqolaOchiq kirish20143 iqtibosABIPersonalized Dendritic Cell-Based Tumor Immunotherapy
Nona Janikashvili, Nicolas Larmonier, Emmanuel Katsanis
Sharh maqola20093 iqtibosABIClinical relevance of host immunity in breast cancer: from TILs to the clinic
Peter Savas, Roberto Salgado, Carsten Denkert +4
Sharh maqola20153 iqtibosABICAR-NK cells: A promising cellular immunotherapy for cancer
Guozhu Xie, Han Dong, Yong Liang +3
Sharh maqola20203 iqtibosABIBispecifics, trispecifics, and other novel immune treatments in myeloma
Guido Lancman, Joshua Richter, Ajai Chari
Sharh maqola20203 iqtibosABIAntibody drug conjugate: the “biological missile” for targeted cancer therapy
Zhiwen Fu, Shijun Li, Sifei Han +2
Sharh maqola20223 iqtibosABIHuman CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
Leonid Cherkassky, Aurore Morello, Jonathan Villena‐Vargas +5
MaqolaOchiq kirish20162 iqtibosABICAR-T cells and combination therapies: What’s next in the immunotherapy revolution?
María C. Ramello, Eric B. Haura, Daniel Abate‐Daga
MaqolaOchiq kirish20172 iqtibosABIThe Next Generation of Cellular Immunotherapy: Chimeric Antigen Receptor-Natural Killer Cells
Jake Moscarelli, David J. Zahavi, Rachael Maynard +1
Sharh maqolaOchiq kirish20222 iqtibosABI